Akebia Therapeutics (AKBA) Competitors $1.87 +0.03 (+1.63%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AKBA vs. ARQT, NRIX, RCUS, KNSA, IMCR, OCUL, MESO, TVTX, NTLA, and PRAXShould you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), Intellia Therapeutics (NTLA), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Akebia Therapeutics vs. Arcutis Biotherapeutics Nurix Therapeutics Arcus Biosciences Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Travere Therapeutics Intellia Therapeutics Praxis Precision Medicines Akebia Therapeutics (NASDAQ:AKBA) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment. Is AKBA or ARQT more profitable? Akebia Therapeutics has a net margin of -27.07% compared to Arcutis Biotherapeutics' net margin of -140.97%. Akebia Therapeutics' return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-27.07% N/A -20.57% Arcutis Biotherapeutics -140.97%-119.11%-45.95% Does the media refer more to AKBA or ARQT? In the previous week, Arcutis Biotherapeutics had 10 more articles in the media than Akebia Therapeutics. MarketBeat recorded 11 mentions for Arcutis Biotherapeutics and 1 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.83 beat Arcutis Biotherapeutics' score of 0.63 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, AKBA or ARQT? Akebia Therapeutics has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$169.88M2.40-$51.92M-$0.23-8.13Arcutis Biotherapeutics$138.71M12.54-$262.14M-$1.79-8.30 Which has more risk and volatility, AKBA or ARQT? Akebia Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Does the MarketBeat Community favor AKBA or ARQT? Akebia Therapeutics received 355 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. However, 64.13% of users gave Arcutis Biotherapeutics an outperform vote while only 63.79% of users gave Akebia Therapeutics an outperform vote. CompanyUnderperformOutperformAkebia TherapeuticsOutperform Votes41463.79% Underperform Votes23536.21% Arcutis BiotherapeuticsOutperform Votes5964.13% Underperform Votes3335.87% Do institutionals and insiders believe in AKBA or ARQT? 33.9% of Akebia Therapeutics shares are held by institutional investors. 4.1% of Akebia Therapeutics shares are held by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer AKBA or ARQT? Akebia Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 301.07%. Arcutis Biotherapeutics has a consensus price target of $15.50, suggesting a potential upside of 4.31%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Akebia Therapeutics is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryAkebia Therapeutics beats Arcutis Biotherapeutics on 12 of the 18 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKBA vs. The Competition Export to ExcelMetricAkebia TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$408.00M$6.87B$5.18B$9.31BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-8.1310.80127.8817.55Price / Sales2.40286.451,262.65139.48Price / CashN/A56.6541.1037.95Price / Book-11.695.394.894.92Net Income-$51.92M$152.04M$119.61M$225.78M7 Day Performance-5.56%-5.54%14.55%-1.47%1 Month Performance4.47%0.33%17.43%5.36%1 Year Performance62.61%16.04%35.33%22.71% Akebia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKBAAkebia Therapeutics3.538 of 5 stars$1.87+1.6%$7.50+301.1%+62.6%$408.00M$169.88M-8.13167ARQTArcutis Biotherapeutics0.8059 of 5 stars$13.31+4.9%$15.50+16.5%+509.0%$1.56B$138.71M-7.58150Options VolumeNews CoverageNRIXNurix Therapeutics2.8431 of 5 stars$21.13+4.2%$30.35+43.6%+133.3%$1.50B$56.42M-6.97300RCUSArcus Biosciences2.7843 of 5 stars$16.25+1.1%$34.00+109.2%-11.3%$1.49B$117M-5.11500KNSAKiniksa Pharmaceuticals2.6661 of 5 stars$20.50+1.5%$36.60+78.5%+13.9%$1.48B$384.10M-147.36220Positive NewsIMCRImmunocore2.6216 of 5 stars$29.12+0.7%$65.64+125.4%-54.2%$1.46B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.797 of 5 stars$9.04+4.0%$16.71+84.9%+129.5%$1.42B$58.44M0.00267Positive NewsMESOMesoblast1.2998 of 5 stars$12.16+3.4%$11.50-5.4%+484.6%$1.39B$5.90M0.0080News CoverageGap UpTVTXTravere Therapeutics2.7223 of 5 stars$17.65+1.9%$22.62+28.1%+97.9%$1.38B$145.24M-3.81460Positive NewsNTLAIntellia Therapeutics4.1809 of 5 stars$13.50+4.7%$54.94+306.9%-57.3%$1.37B$36.28M-2.37600Short Interest ↑PRAXPraxis Precision Medicines2.4892 of 5 stars$72.35+3.1%$146.33+102.3%+372.3%$1.35B$2.45M-7.06110High Trading Volume Related Companies and Tools Related Companies ARQT Alternatives NRIX Alternatives RCUS Alternatives KNSA Alternatives IMCR Alternatives OCUL Alternatives MESO Alternatives TVTX Alternatives NTLA Alternatives PRAX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKBA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
